Newsletter Michael Murphy Target for $ARTH $12
You can now get the names and symbols for all five $20-for-$1 biotechs for less than $12 each through a monthly subscription to New World Investor. Just CLICK HERE.
Company #2 - Bleeding is a huge problem, whether it is during surgery, at the scene of an accident, or on the battlefield. Much of the cost of an operation depends on how long it takes - the surgeon and support staff's time, and use of the expensive operating room. About 40% to 50% of operating time is spent controlling bleeding. An accident or battlefield injury can mean the victim bleeds out and dies before they can get to needed treatment.
What if a doctor or EMT could paint a clear liquid on any bleeding - even a spurting severed artery - and stop the bleeding in three to ten seconds? Leaving a clear film for observation and further surgery? And what if the FDA agreed to regulate that liquid as a device, with a faster and cheaper path to approval than a drug? What if the company only needed one clinical trial for approval? And the clinical trial is done and was successful?
That's the current position of Company #2. I expect FDA approval by the end of this year - maybe before Halloween. This is a $5 billion market in the US alone, plus probably another $5 billion in the rest of the world. Then there's the other 200 applications the company has identified - burns, diabetic ulcers, bed sores.... The stock sells for less than 80¢ a share with a market capitalization just over $100 million. Can it get to $2 billion and give you $20-for-$1? $2 billion for a dominant bleeding control product is nothing for a company like Johnson & Johnson that has several products in this area.
